Compare TSQ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSQ | ENGN |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 117.2M |
| IPO Year | 2014 | 2023 |
| Metric | TSQ | ENGN |
|---|---|---|
| Price | $5.37 | $1.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.50 | ★ $21.08 |
| AVG Volume (30 Days) | 55.8K | ★ 667.0K |
| Earning Date | 05-11-2026 | 06-11-2026 |
| Dividend Yield | ★ 12.80% | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,380,000.00 | N/A |
| Revenue This Year | $2.22 | N/A |
| Revenue Next Year | $0.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $1.40 |
| 52 Week High | $7.97 | $12.25 |
| Indicator | TSQ | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 55.13 |
| Support Level | $5.34 | $1.67 |
| Resistance Level | $5.52 | $1.95 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 43.89 | 80.56 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.